RHEBL1 Activators encompass a diverse array of chemical compounds that enhance the functional activity of RHEBL1 through various specific biochemical pathways. Forskolin, by catalyzing adenylyl cyclase, raises intracellular cAMP, which indirectly potentiates RHEBL1 by activating PKA; the activated PKA can phosphorylate proteins that interact with or regulate RHEBL1's GTPase activity, thereby enhancing its role in the mTOR cascade. Similarly, Ionomycin and W-7 Hydrochloride impact intracellular calcium levels and calmodulin activity, respectively; these alterations in calcium signaling can augment RHEBL1's involvement in pathways sensitive to calcium fluxes. Phorbol 12-myristate 13-acetate (PMA) stimulates PKC, which modulates the phosphorylation landscape, potentially increasing RHEBL1 activity. Okadaic Acid prevents the dephosphorylation of proteins within RHEBL1's pathway, sustaining its active state, while LY294002 and PD 98059 manipulate PI3K and MEK pathways, respectively, to reduce inhibitory feedback on RHEBL1's function.
The interaction of Sphingosine-1-phosphate with its receptors initiates a signaling cascadethat can culminate in the activation of RHEBL1, particularly influencing cellular mechanisms like migration and survival where RHEBL1 is a key player. The indirect effects of kinase inhibitors such as Rapamycin, SB 203580, and U0126, through their targeted inhibition of mTOR, p38 MAPK, and MEK1/2 respectively, can create a signaling milieu that favors RHEBL1 activation. Rapamycin, in particular, can induce a compensatory upregulation of RHEBL1 activity as part of the cell's attempt to re-engage mTOR signaling. Additionally, Zoledronic Acid, by inhibiting farnesyl pyrophosphate synthase, may inadvertently increase the functional activation of RHEBL1 by enhancing its membrane association, which is essential for its activation and subsequent signaling. Collectively, these RHEBL1 Activators, through their precise and varied influence on cellular signaling networks, facilitate the enhancement of RHEBL1-mediated functions, providing a rich tapestry of biochemical interactions that underscore the multifaceted regulation of this GTPase in cellular signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $94.00 $259.00 | 2 | |
Ionomycin acts as a calcium ionophore, increasing intracellular calcium levels. This can enhance the calmodulin-dependent activation of signaling cascades, indirectly augmenting RHEBL1 activity within the calcium-sensitive pathways it participates in. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a PKC activator. PKC activation can lead to downstream effects that include the activation of RHEBL1 by altering its phosphorylation state and thus promoting its role in the mTOR signaling pathway. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid inhibits protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels within the cell. This can indirectly enhance RHEBL1 function by preventing the dephosphorylation of proteins within its signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which can lead to altered signaling dynamics, indirectly enhancing RHEBL1's function in pathways where PI3K signaling is inhibitory to RHEBL1's role. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is an MEK inhibitor, which may enhance RHEBL1 activity by reducing ERK pathway feedback inhibition that can regulate RHEBL1 GTPase activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which can lead to a compensatory increase in RHEBL1 activity as the cell attempts to restore mTOR signaling by activating upstream effectors like RHEBL1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 selectively inhibits p38 MAPK. Inhibition of p38 can shift the balance of cellular signaling to enhance RHEBL1 activity within its associated signaling pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P engages with G-protein-coupled receptors to activate signaling pathways that can include RHEBL1 activation as part of the downstream response, particularly in processes like cell migration and survival. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
W-7 is a calmodulin antagonist that when inhibiting calmodulin, can lead to the enhancement of RHEBL1 activity by affecting associated signaling pathways that are regulated by calcium/calmodulin. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $90.00 $251.00 | 5 | |
Zoledronic acid inhibits farnesyl pyrophosphate synthase, potentially increasing prenylation activity on other pathways, which may indirectly enhance RHEBL1's role in signaling by increasing its membrane association and functional activation. | ||||||